Brief Chemotherapy and Involved-Region Irradiation for Limited-Stage Diffuse Large-Cell Lymphoma: An 18-Year Experience From the British Columbia Cancer Agency PURPOSE: We conducted a retrospective ...

Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. Fifty patients who had relapsed (n=25) after or were resistant (n = 25) to chemotherapy were ...

Genzyme Corp held its second investor meeting in two months to argue that its most promising experimental drug will capture five times the sales that Sanofi-Aventis has assumed in a hostile $18.5 ...

All patients were nursed in positive pressure HEPA filtered rooms. Ciprofloxacin, amphotericin suspension and itraconazole or fluconazole were commenced pre-transplant. Pneumocystis pneumonia ...

Combining Fludara (fludarabine), Cytoxan (cyclophosphamide), and Rituxan (rituximab) was safer and produced a higher response than pairing Campath (alemtuzumab) with Fludara and Cytoxan in patients ...

The speculation about Genzyme's Campath is over. The company, now a unit of Sanofi ($SNY), is pulling the plug. Why? To prepare the way for Lemtrada, a multiple ...

British-based BTG received more good news this week regarding Campath after its licensee, Genzyme Corp, and Bayer Schering Pharma AG announced they had kicked off a Phase III trial testing the drug’s ...

Bayer has signed a major deal with Genzyme Corp, including the transfer of its haematological oncology portfolio, and certain rights to Campath, which could net the German group up to $2.8 billion.

The humanized monoclonal antibody CAMPATH-1H (alemtuzumab) was approved in 2014 for the treatment of patients with relapsing–remitting multiple sclerosis, but the CAMPATH story began more than 30 ...

One of the big sticking points in the potential Sanofi-Aventis/Genzyme deal has been sales estimates for Campath, the company's leukemia drug that it's developing for multiple sclerosis. Genzyme has ...

Chlorambucil was given from October to December 1997; four cycles of mitoxantrone, vincristine, and prednisone were given from November 1999 to February 2000; and three cycles of fludarabine were ...